Tarlatamab - Which company makes Imdelltra?

Tarlatamab-Imdelltra is an innovative bispecific antibody drug developed by AMGEN INC. As the world's leading biopharmaceutical company, Amgen has a long-standing history in the field of tumor immunotherapy and has launched many well-known drugs such as aflibercept and panitumumab. The development and launch of talatumumab marks a new breakthrough for Amgen in small cell lung cancer (SCLC), a field with limited treatment options.

Small cell lung cancer is a type of malignant tumor that progresses rapidly, metastasizes early, and has a high recurrence rate. In particular, the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) has been in trouble for a long time. Although traditional platinum-based chemotherapy can achieve a certain initial response, most patients will experience disease progression within a few months, and subsequent treatment options are very limited. The emergence of talatumumab provides new hope for patients who have failed platinum-based chemotherapy.

From a mechanism perspective, talatumumab is a bispecificT cell connector (BiTE) antibody that can simultaneously recognize the DLL3 target on the tumor surface and the CD3 molecule on the surface of T cells. This dual binding method allows T cells to be accurately guided around cancer cells, thereby triggering an immune attack and killing cancer cells. Since DLL3 is generally highly expressed in small cell lung cancer tissues and less frequently found in normal tissues, the drug has better selectivity and targeting.

In terms of indications, the United StatesFDA approved talatumumab in May 2024 for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed during or after platinum-based chemotherapy. This population has had few effective treatment options in the past, so the approval of this drug is landmark.

In general, talatumumab is an innovative drug developed and produced by Amgen. It not only demonstrates the advantages of combining immunotherapy and bispecific antibody technology, but also provides a new treatment path for patients with small cell lung cancer. With the gradual deepening of clinical application, talatumumab is expected to change the treatment landscape of this highly lethal tumor.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html